Only 67% of high-cardiovascular-risk patients are treated with lipid-modifying therapy (LMT), of which only 7% used a high-potency statin. Among LMT users, 69% of those taking high-potency statins, 70% taking standard-potency statins, and 20% receiving non-statin LMTs attains an LDL-C goal <100 mg/dL. This was found in a study recently published in Clinical Therapeutics. In this study the use of lipid-modifying therapy and attainment of LDL-C goals were investigated in a population at high cardiovascular risk, using data from the PHARMO Database Network. Results suggest that improvements in the treatment of cardiovascular disease in the Netherlands are needed because many high-cardiovascular-risk patients are not being treated with the maximally tolerated dose of statin. Increased use of statins and LMTs overall, as well as increased high-potency statin use, may be required to reduce cardiovascular risk in this population, and if that does not suffice, ultimately the addition of newer therapeutic options might be needed.
To read more, please click here.